OraPharma and Hu-Friedy Launching Co-Marketing Program
OraPharma, Inc., manufacturers of ARESTIN® (Minocycline Hydrochloride) Microspheres, 1 mg, recently launched a unique co-marketing agreement with Hu-Friedy® Mfg., Co., Inc. for the purpose of increasing the diagnosis and . . .
ORAPHARMA AND HU-FRIEDY LAUNCHING CO- MARKETING PROGRAM
TO PROMOTE PERIODONTAL DISEASE AWARENESS
JOINT PROGRAM BUNDLES HU-FRIEDY’S COLORVUE® PROBE WITH
ORAPHARMA’S PERIODONTAL DISEASE EDUCATION CAMPAIGN
WARMINSTER, PA, August 23, 2006 - OraPharma, Inc., manufacturers of ARESTIN® (Minocycline Hydrochloride) Microspheres, 1 mg, recently launched a unique co-marketing agreement with Hu-Friedy® Mfg., Co., Inc. for the purpose of increasing the diagnosis and treatment of periodontal disease.
Under the terms of the agreement, OraPharma will distribute more than 10,000 specially-assembled co-branded sample kits to dental professionals throughout the United States. Each kit will contain Hu-Friedy’s popular Colorvue® replacement plastic probe, periodontal disease information and a coupon good for the Colorvue® probe replacement tips.
According to Chantel Willis, Associate Market Leader, Diagnostics of Hu-Friedy, “The Colorvue® probe’s vivid yellow tip with black markings increases visibility and provides more accurate periodontal assessments. We believe that providing dental professionals with a Colorvue® sample will encourage them to conduct a thorough six-point probing during each patient visit.”
Both OraPharma and Hu-Friedy believe that improving the rate of periodontal disease diagnosis and treatment are extremely important based on the following statistics:
“ Periodontal disease affects more than 50 million people across all age groups and demographic categories1
“ Periodontal Disease is a leading cause of adult tooth loss2
“ The Surgeon General has issued a statement3 regarding the possible relationship between periodontal disease and medical conditions such as cardiovascular disease, diabetes, osteoporosis and pre-term, low birth weight babies.
“Once periodontal disease is diagnosed, scaling and root planning (SRP) is the traditional course of treatment,” explains John Lenart, OraPharma’s senior product
manager. “However, recent clinical studies have proven that using ARESTIN® as an adjunct to SRP is much more effective than SRP alone in controlling periodontal pathogens, and achieving measurably better clinical outcomes 4.”
The OraPharma/Hu-Friedy sample kits will begin shipping in mid-June, for more information call your local OraPharma account manager or log onto www.arestin.com.
References:
1 Preboth, M. Minocycline Approved for Adult Periodontitis. Amer Fam Phys. 2001; 64(5):876.
2 Lewis, C. Fighting Gum Disease: How to Keep Your Teeth. FDA Consum. 2002 May-Jun; 36(3):16-22.
3 US Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General. Rockville, MD: US Department of Dental and Craniofacial Research, National Institutes of Health, 2000.
4 Research on file at OraPharma, Inc.
<< Back
